Want to see NEUP full AI Analyst Report?
Top Page
Neuphoria Therapeutics
(NASDAQ:NEUP)
Select Model
Select Model
Rating:48Neutral
Price Target:
$3.50
▼(-9.33% Downside)
Action:Reiterated
Date:09/19/26
The score is held down primarily by very weak profitability and renewed cash burn, which outweigh a comparatively strong, low-leverage balance sheet. Technically, the stock shows weak momentum and remains below longer-term moving averages, with only an oversold signal offering some near-term support. A positive merger/financing event helps, but valuation remains difficult to justify given ongoing losses and no dividend data.
Positive Factors
Low Leverage and Equity Base
A low-debt balance sheet provides financial flexibility while the sizable equity base offers capacity to support development and strategic investment. Although returns remain weak, limited leverage reduces immediate balance-sheet pressure and may help the company pursue its biotech plans without excessive interest obligations.
Negative Factors
Persistent Unprofitability
Persistent losses and an extremely negative net margin show that current business activity is not translating into sustainable earnings. This weak profitability can continue consuming capital, limit internally funded growth, and make the company more dependent on successful development outcomes or additional external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage and Equity Base
A low-debt balance sheet provides financial flexibility while the sizable equity base offers capacity to support development and strategic investment. Although returns remain weak, limited leverage reduces immediate balance-sheet pressure and may help the company pursue its biotech plans without excessive interest obligations.
Read all positive factors
Neuphoria Therapeutics (NEUP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$17.97M
Dividend YieldN/A
Average Volume (3M)15.96K
Price to Earnings (P/E)―
Beta (1Y)1.58
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,411,334
10 Day Avg. Volume11,048
30 Day Avg. Volume15,957
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)16.36
P/FCF Ratio>-0.01
Enterprise Value/Market Cap216.37K
Enterprise Value/Revenue3.31M
Enterprise Value/Gross Profit7.60M
Enterprise Value/Ebitda-414.06K
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Neuphoria Therapeutics Business Overview & Revenue Model
Company Description
Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with...
Neuphoria Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
72
Positive
Cash Flow
18
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.17M | 15.65M | 0.00 | 0.00 | 383.16K |
| Gross Profit | 511.21K | 14.99M | -662.99K | -671.48K | -9.98M |
| EBITDA | -9.15M | -466.20K | -25.98M | -31.48M | -30.75M |
| Net Income | -13.45M | -369.63K | -15.49M | -32.18M | -22.94M |
Balance Sheet | |||||
| Total Assets | 28.71B | 43.44M | 27.65M | 19.39M | 65.30M |
| Cash, Cash Equivalents and Short-Term Investments | 19.87B | 21.59M | 12.61M | 8.06M | 33.56M |
| Total Debt | 34.34K | 226.49K | 272.74K | 582.35K | 693.55K |
| Total Liabilities | 4.11B | 14.57M | 10.16M | 4.74M | 8.40M |
| Stockholders Equity | 24.60B | 28.87M | 17.49M | 14.65M | 56.91M |
Cash Flow | |||||
| Free Cash Flow | -12.35B | 77.23M | -14.68M | -9.85M | -21.75M |
| Operating Cash Flow | -12.35B | 77.23M | -14.68M | -9.85M | -21.75M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 621.64K |
| Financing Cash Flow | 17.92B | 1.53B | 15.11M | 5.81M | 26.99M |
Neuphoria Therapeutics Technical Analysis
Negative
3.86
Price Trends
3.72
Negative
3.96
Negative
4.20
Negative
Market Momentum
-0.11
Positive
30.71
Neutral
12.68
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NEUP, the sentiment is Negative. The current price of 3.86 is above the 20-day moving average (MA) of 3.55, above the 50-day MA of 3.72, and below the 200-day MA of 4.20, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 30.71 is Neutral, neither overbought nor oversold. The STOCH value of 12.68 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NEUP.
Neuphoria Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $23.38M | -104.26 | -0.80% | ― | 27.78% | 52.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $16.10M | -0.38 | -565.55% | ― | -28.53% | 47.55% | |
48 Neutral | $17.97M | -0.47 | -77.03% | ― | ― | ― | |
47 Neutral | $67.71M | -0.41 | -234.45% | ― | ― | 36.23% | |
38 Underperform | $11.26M | -0.38 | -126.02% | ― | ― | 78.51% |
* Healthcare Sector Average
NEUP
Neuphoria Therapeutics
3.39
-12.66
-78.88%
TXMD
TherapeuticsMD
1.96
0.92
88.46%
SINT
Sintx Technologies
2.07
-2.14
-50.83%
RNTX
Rein Therapeutics
0.75
-0.59
-43.73%
BIVI
BioVie
1.20
-0.80
-40.00%
BFRG
BullFrog AI Holdings, Inc.
0.57
-0.90
-61.36%
Neuphoria Therapeutics Corporate Events
Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsPrivate Placements and Financing
Neuphoria Therapeutics to Merge with Scancell Holdings
Positive
Jul 24, 2026
On July 23, 2026, Neuphoria Therapeutics agreed to an all-share merger in which UK-based Scancell Holdings will acquire Neuphoria, creating a combined immunotherapy-focused company that will operate as Scancell and be listed on both Nasdaq and Lon...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.